We searched PubMed for articles published between Jan 1, 2005, and Dec 31, 2017, using the search terms “PML”, “progressive multifocal leukoencephalopathy”, “JCV”, “human polyomavirus”, “antiviral antibodies”, “PML IRIS”, and “natalizumab”. Articles were also identified by searches of the authors' own files and the reference lists of selected papers. There were no language restrictions. The final reference list was generated on the basis of relevance to the topic of the Review, with a focus on
ReviewPathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned
Introduction
More than a decade has passed since the first reports of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis who were taking natalizumab in phase 3 clinical trials.1, 2, 3 Natalizumab is a monoclonal antibody to α4β1 and α4β7 integrins that blocks inflammatory cell entry into the brain and can prevent multiple sclerosis-related clinical relapses. The co-occurrence of PML and multiple sclerosis was unanticipated, because these disorders have little in common except for the destruction of myelin: PML is a JC virus (JCV)-induced lytic brain infection, whereas relapsing-remitting multiple sclerosis is an autoimmune disorder. PML was quickly associated with natalizumab treatment because patients with multiple sclerosis had been treated with other immune therapies for decades without reports of PML.1, 2, 3, 4 The initial prevalence of natalizumab-associated PML in patients with multiple sclerosis was estimated to be one in 1000.4 More than 750 PML cases have now been confirmed among natalizumab-treated patients, with a fatality rate higher than 20% and substantial morbidity in survivors.5 The prevalence of PML among patients treated with natalizumab for more than 24 months, with antibody evidence of JCV and previous immunosuppressant exposure, has reached at least one in 70—much higher than the prevalence of any other opportunistic infection in this setting.6, 7 Risk-profiling analyses of patients who are positive for anti-JCV antibody gave an estimated cumulative PML probability over 6 years of 1·7% (95% CI 1·4–2·1).8 A few reports of PML in patients taking other treatments for multiple sclerosis, such as dimethyl fumarate and fingolimod, have been published.9, 10, 11, 12, 13 However, the prevalence of PML in patients with multiple sclerosis who are taking other immune-modulating therapies is much lower than that associated with natalizumab, perhaps one in 10 000 to one in 100 000. Although outcomes for patients with PML have improved with early detection and initiation of immune reconstitution,5 PML is a serious and sometimes lethal disorder, and the clinical management of patients with multiple sclerosis—including PML risk assessment and surveillance—remains challenging.
Investigations in patients with multiple sclerosis have contributed to improved understanding of the pathogenesis of PML. This knowledge is crucial in recognising therapy-associated risks of PML, establishing evidence-based monitoring strategies for patients, and informing the selection of effective treatments for individuals with multiple sclerosis. In this Review, we explore several areas of progress. First, we discuss molecular aspects of PML pathogenesis and the cell-specific involvement of JCV infection leading to PML, which are generally applicable to all cases of PML regardless of underlying diseases. Second, we consider the central role of MRI in the diagnosis of PML and outline how treated patients can be monitored to minimise morbidity and advance our understanding of aspects of pathophysiology. Third, we highlight new insights of clinical value in early PML detection.
Section snippets
JCV infection and PML pathogenesis
PML is usually characterised as a rare disease caused by JCV, a common polyomavirus named from the initials of the first patient from whom the virus was isolated.14 PML develops almost exclusively in patients with a compromised immune system, particularly when cell-mediated immune responses are involved. For example, PML was initially reported in patients with underlying neoplastic diseases, mostly lymphoproliferative diseases, and in patients with organ transplants who had undergone immune
Early detection, diagnosis, and management of PML
Brain imaging makes a vital contribution to the diagnosis of PML, which also routinely requires the identification of active CNS pathology and JCV in the brain.63 Indeed, PML diagnosis cannot be verified without an MRI lesion. The sensitivity of MRI in identifying PML lesions has made it the modality of choice in monitoring natalizumab-treated patients with multiple sclerosis for early detection of PML. MRI has also contributed to our understanding of the clinical stages of PML, which depend on
Towards successful risk-mitigation strategies
A risk-mitigation strategy was developed with the aim of protecting patients from PML in the setting of natalizumab therapy.103 The fundamentals have been actively discussed and variably applied.6, 7, 104, 105, 106, 107, 108 However, the ideal of witnessing plummeting incidence of PML cases has not yet materialised.109 We summarise our own suggestions, which are based on a recent algorithm79 and a review of available data (table 3). We propose that surveillance be guided by estimated
Conclusion and future directions
Substantial progress in understanding JCV and PML has been made in the past decade. Close observation of patients with natalizumab-associated PML and additional cases of PML seen in patients with multiple sclerosis have provided an opportunity to learn more about the molecular biology of JCV and to make some progress in understanding the evolution of risk and invasion of the brain. Enhanced identification of high-risk patients has allowed the use of MRI to evolve such that detection of PML
Search strategy and selection criteria
References (114)
- et al.
Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy
Mult Scler Relat Disord
(2016) - et al.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Lancet Neurol
(2017) - et al.
Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy
Lancet
(1971) - et al.
Progressive multifocal leukoencephalopathy
Neurol Clin
(1984) - et al.
Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy
Virology
(2009) - et al.
The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leucoencephalopathy
Clin Diagn Virol
(1995) - et al.
Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants
J Clin Virol
(2013) - et al.
Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: A report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project
Blood
(2009) - et al.
Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy
J Neurol Sci
(2014) - et al.
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
N Engl J Med
(2005)
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
N Engl J Med
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
N Engl J Med
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
N Engl J Med
Medical information. Tysabri (natalizumab) safety update
Reassessing the risk of natalizumab-associated PML
J Neurovirol
PML in a patient treated with dimethyl fumarate from a compounding pharmacy
N Engl J Med
PML in a patient without severe lymphocytopenia receiving dimethyl fumarate
N Engl J Med
PML in a patient with lymphocytopenia treated with dimethyl fumarate
N Engl J Med
Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
Neurol Neuroimmunol Neuroinflamm
Fingolimod-associated PML in a patient with prior immunosuppression
Neurology
Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy
Ann Neurol
Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era
Eur J Clin Microbiol Infect Dis
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain
Clin Microbiol Rev
Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy
J Virol
Opportunistic DNA recombination with Epstein-Barr virus at sites of control region rearrangements mediating JC virus neurovirulence
J Infect Dis
Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy
J Infect Dis
Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera
Microbiol Immunol
Influence of JC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy
J Neurovirol
Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV)
Adv Exp Med Biol
Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy
J Neurovirol
JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy
J Virol
Lack of JC viral genomic sequences in multiple sclerosis brain tissue by polymerase chain reaction
Ann Neurol
JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis
Ann Neurol
JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route
J Virol
JC polyomavirus mutants escape antibody-mediated neutralization
Sci Transl Med
RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks
J Exp Med
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab
Mult Scler
Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors
J Infect Dis
JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab
AnnNeurol
Parent-to-child transmission is relatively common in the spread of the human polyomavirus JC virus
J Clin Microbiol
JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab
JAMA neurology
Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy
Clin Dev Immunol
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome
Brain
Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier
J Infect Dis
Natalizumab-induced POU2AF1/Spi-B upregulation: a possible route for PML development
Neurol Neuroimmunol Neuroinflamm
Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area
Curr Opin Neurol
Involvement of JC virus-infected mono-nuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy
N Engl J Med
JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals
Clin Infect Dis
Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus
J Clin Microbiol
Anti-JC virus antibodies: implications for PML risk stratification
Ann Neurol
Cited by (149)
Epidemiology of progressive multifocal leukoencephalopathy in Japan and effectiveness of mefloquine: A retrospective analysis of a nationwide inpatient database
2023, Journal of the Neurological SciencesLatin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs
2023, Multiple Sclerosis and Related DisordersExtended-interval dosing of natalizumab in NOVA
2023, The Lancet NeurologyNeural stem cell engineering for the treatment of multiple sclerosis
2022, Biomedical Engineering Advances